Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc filed a Form 6-K reporting a transaction notification dated
GSK plc reports that, acting through Merrill Lynch International, it purchased 214,694 ordinary shares of 31.25p each on 20 August 2025 as part of its ongoing buyback programme under the non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the Company has purchased 24,790,338 ordinary shares. The purchased shares will be held as Treasury shares bringing the total held in treasury to 242,924,721. The Company has 4,072,467,013 ordinary shares in issue excluding Treasury shares and the total number of voting rights is 4,072,467,013. The percentage of voting rights attributable to treasury shares is 5.97%.
GSK plc reported a purchase of 211,358 ordinary shares of 31.75p each on 19 August 2025 under its announced buyback programme executed by Merrill Lynch International. The shares will be held as treasury stock. Since the non-discretionary broker agreement dated 4 June 2025, the Company has bought 24,575,644 ordinary shares. After this transaction GSK will hold 242,710,027 shares in treasury and will have 4,072,681,707 ordinary shares in issue (excluding treasury), giving a total voting rights denominator of 4,072,681,707 and treasury shares representing 5.96% of voting rights. The filing lists detailed trade-by-trade prices and venues for the aggregated purchases.
GSK plc submitted a Form 6-K reporting a transaction notification dated August 19, 2025. The filing identifies the security by ISIN US37733W2044 and lists three reported volumes: 3,328.441, 84, and 61.934. The report does not disclose prices, counterparty names, or the specific nature of each transaction in the supplied text. No financial amounts, proceeds, gains, or other narrative explanation appear in the provided content. Because key fields such as price and transaction description are not present, the filing records activity in the listed share lots but provides limited information to assess material investor impact.
GSK plc reported a transaction in its ordinary shares on 18 August 2025 under its ongoing buyback programme. Acting through Merrill Lynch International, the Company purchased 221,293 ordinary shares at prices shown in the schedule, with an average price reported as 1,437.72p. The purchased shares will be held as Treasury shares.
Since entering the non-discretionary broker agreement on 4 June 2025, GSK has bought 24,364,286 ordinary shares. After this trade GSK will hold 242,498,669 shares in treasury and will have 4,072,893,065 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,072,893,065 and treasury shares represent 5.95% of voting rights.
GSK plc announced a purchase of 436,588 ordinary shares on 15 August 2025 executed by Merrill Lynch International under its non-discretionary buyback agreement dated 4 June 2025. The shares were bought on the London Stock Exchange and CBOE Europe venues at prices between 1,414.50p and 1,429.50p and will be held as Treasury shares.
Since 4 June 2025 the company has purchased a total of 24,142,993 ordinary shares under the programme. After this transaction GSK will hold 242,277,376 shares in treasury, have 4,073,114,358 ordinary shares in issue (excluding treasury) and a total number of voting rights of 4,073,114,358. The percentage of voting rights attributable to treasury shares is 5.95%.
GSK plc reports a purchase of 501,689 ordinary shares on 14 August 2025 under its ongoing buyback programme executed by Merrill Lynch International. The shares were bought on the London Stock Exchange at prices between 1,401.50p and 1,415.50p and will be held as Treasury shares. Since the non-discretionary broker agreement dated 4 June 2025, the company has purchased 23,706,405 ordinary shares. After this transaction GSK will hold 241,840,788 shares in treasury and have 4,073,550,458 ordinary shares in issue (excluding treasury), giving a total of 4,073,550,458 voting rights and treasury shares representing 5.94% of voting rights.
GSK plc executed a purchase of 306,478 ordinary shares of 31.25 pence each on 13 August 2025 at a volume-weighted average price of 1,424.64p per share. The shares were bought through Merrill Lynch International under the company’s existing buyback programme and will be held as Treasury shares.
Since the non-discretionary agreement announced on 4 June 2025, GSK has purchased 23,204,716 ordinary shares. Following this transaction the company holds 241,339,099 ordinary shares in treasury and has 4,074,052,147 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,074,052,147, and the percentage of voting rights attributable to treasury shares is 5.92%.
GSK plc repurchased 495,245 ordinary shares of 31 3/4 pence on 12 August 2025 through its corporate stockbroker Merrill Lynch International, paying between 1,395.50p and 1,405.00p with a volume-weighted average price of 1,401.27p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme entered into on 4 June 2025.
Since 4 June 2025 the company has purchased 22,898,238 ordinary shares. Following this trade GSK will hold 241,032,621 ordinary shares in treasury and have 4,074,358,625 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,074,358,625, and ordinary shares held in treasury represent 5.92% of voting rights.
GSK plc reported that multiple senior managers, including CEO Emma Walmsley and CFO Julie Brown, acquired Ordinary Shares under the company’s Share Reward Plan. Each named participant purchased 18 Ordinary Shares (comprised of 9 partnership shares and 9 matching shares) at a price of £14.0845 per share on 11 August 2025. All transactions were executed on the London Stock Exchange (XLON). The report lists several other executives and senior officers making identical purchases under the same plan; the disclosures are routine notifications of employee share-plan acquisitions.